Opko Health Inc (OPK)

[tomsylver]

Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating and $12 price target on Opko Health (NYSE: OPK) following the Pfizer deal for growth hormone.
Vanjani commented, "While OPKO will retain much of the responsibilities for developing hGH-CTP, the company will receive significant cash up front, significant regulatory milestones, and the ability to use Pfizer's marketing muscle to help adoption of hGH-CTP if and when the product is approved. Overall, we view the partnership as positive. Pfizer's involvement will help to de-risk the program as well as drive larger worldwide sales. We maintain our Outperform rating."